GLP-3RT Triple Agonism: The Science Behind GLP-1, GIP, and Glucagon Receptor Research

Introduction

The last decade of metabolic research has been defined by incretin-based therapies — compounds that harness the body’s own gut hormone signaling to modulate appetite, glucose metabolism, and energy expenditure. The progression from single GLP-1 agonists to dual GLP-1/GIP agonists, and now to triple GLP-1/GIP/glucagon receptor agonists, represents one of the most rapidly advancing areas in pharmacological research.^[1]

Triple-agonist peptides — compounds designed to simultaneously activate GLP-1, GIP, and glucagon receptors — have emerged as a subject of intense scientific interest. The rationale is compelling: each receptor axis contributes complementary metabolic effects, and combining all three may produce synergistic outcomes that neither single nor dual agonists can achieve.

The Three Receptor Targets

GLP-1 (Glucagon-Like Peptide-1) Receptors

GLP-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. Its receptor is expressed broadly in the pancreas, brain, heart, kidney, and gut. GLP-1 receptor activation:

Stimulates glucose-dependent insulin secretion from beta cells
Suppresses glucagon release in hyperglycemic states
Delays gastric emptying (reducing nutrient absorption rate)
Produces central appetite suppression via hypothalamic pathways
Has demonstrated cardiovascular protection in multiple large trials^[2]

GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptors

GIP is the other major incretin hormone, secreted from intestinal K-cells. Its receptor is expressed in the pancreas, adipose tissue, bone, and brain. GIP receptor activation:

Potentiates insulin secretion post-meal (synergistically with GLP-1)
Promotes lipid clearance in adipose tissue
Plays a role in bone metabolism and energy storage
Reduces nausea-related side effects when combined with GLP-1 agonism^[3]

Glucagon (GCG) Receptors

The glucagon receptor is abundant in the liver, heart, and kidney. Counterintuitively, glucagon receptor agonism — when balanced with GLP-1 activity — offers additional metabolic benefits:

Increases hepatic fat oxidation and reduces hepatic lipid accumulation
Increases energy expenditure (thermogenesis) independent of appetite effects
Reduces food intake through distinct hypothalamic pathways
Activates PCSK9 degradation, potentially improving LDL cholesterol profiles^[4]

The liver is rich in glucagon receptors but lacks GLP-1 or GIP receptors — making glucagon agonism critical for direct hepatic metabolic effects.^[5]

The Research Case for Triple Agonism

Retatrutide (LY3437943) — Lead Research Compound

The most extensively studied GLP-1/GIP/glucagon triple agonist in published literature is retatrutide, developed by Eli Lilly and Company. It is a single 39-amino-acid peptide engineered from a GIP peptide backbone to simultaneously activate all three receptor targets.

Phase 2 clinical trial data published in the New England Journal of Medicine (2023) showed:

Up to 24.2% mean weight reduction at 48 weeks in participants with obesity receiving the 12mg dose
25% of participants achieved ≥30% weight reduction from baseline — a level historically achievable only through bariatric surgery
Weight loss trajectory at 48 weeks had not yet plateaued, suggesting continued efficacy potential^[6]

Phase 2 T2D trial data: HbA1c improved by 2.2%, with 82% of participants achieving HbA1c ≤6.5%.

72% of participants who had prediabetes at baseline reverted to normoglycemia.^[4]

Cardiometabolic Profile Improvements

Participants in retatrutide trials showed improvements across multiple cardiometabolic markers:

Reduced waist circumference
Lower systolic and diastolic blood pressure
Improved fasting glucose and insulin
Improved lipid profiles (except HDL, which was unchanged)
LDL reductions of approximately 20% — likely via glucagon-mediated PCSK9 modulation^[4][6]

Liver Fat Research

A Phase 2a trial published in Nature Medicine (2024) specifically investigated retatrutide’s effects on metabolic dysfunction-associated steatotic liver disease (MASLD). Results showed:

42.9% relative reduction in liver fat at 24 weeks (1mg dose)
57.0% relative reduction (4mg dose)
81.4% relative reduction (8mg dose)
82.4% relative reduction (12mg dose)
Placebo group: +0.3% change

All active doses achieved statistical significance vs. placebo (P < 0.001).^[7]

This is clinically significant because the liver has no GLP-1 or GIP receptors — the dramatic hepatic fat reductions observed are attributed primarily to the glucagon receptor agonist component, working through hepatic fatty acid oxidation, mitochondrial function improvement, and anti-fibrotic pathways.

Mechanisms Beyond Weight Loss

Triple receptor agonism creates biological effects that single or dual agonists cannot replicate:

Energy Expenditure Increase

Glucagon receptor activation independently increases thermogenesis and metabolic rate — an effect not seen with GLP-1 agonists alone. This means triple agonists may produce greater caloric deficit through a dual mechanism: appetite suppression (GLP-1/GIP-mediated) AND increased energy expenditure (glucagon-mediated).^[3]

Reduced GI Side Effects

GIP receptor agonism appears to attenuate the nausea and vomiting commonly associated with GLP-1 receptor agonists. Phase 2 retatrutide trials confirmed that gastrointestinal adverse events were transient, primarily occurring during dose escalation, and were predominantly mild-to-moderate.^[6]

Metabolic Flexibility

The combination of all three receptor axes may promote “metabolic flexibility” — the ability to efficiently switch between glucose and fat as fuel sources. Glucagon’s role in amino acid metabolism, combined with GIP’s lipid-handling effects and GLP-1’s glycemic modulation, creates a uniquely comprehensive metabolic signaling environment.^[8]

Research Stage and Regulatory Context

It is essential to frame this research honestly:

Retatrutide (LY3437943) is currently in Phase 3 clinical trials for obesity and T2DM — data is not yet available
No GLP-1/GIP/glucagon triple agonist peptide has received FDA approval
All data cited is from Phase 1 and Phase 2 trials
Gastrointestinal adverse events are the most common reported side effects, manageable through dose titration
Long-term safety beyond 48 weeks is not yet characterized

Research-grade triple agonist peptides are available for in-vitro mechanistic studies investigating receptor binding dynamics, metabolic pathway signaling, and comparative pharmacology across GLP-1, GIP, and glucagon receptor systems.

At Osirix, all BPC-157 is sold strictly as a research compound — for in-vitro study purposes only. Every batch is third-party tested in the EU with verified purity certificates available.

References

[1]PMC Review. Triple Agonism Based Therapies for Obesity. PMC, 2025.
[2]Incretin Review. GLP-1 Receptor Agonists in Obesity Management. Various.
[3]Road Towards Triple Agonists Review. PMC, 2024.
[4]Frias JP et al. Retatrutide in Type 2 Diabetes. The Lancet, 2023.
[5]Sanyal AJ. Investigators Share Data on Retatrutide Triple Therapy. ADA Meeting News, 2024.
[6]Jastreboff AM et al. Retatrutide for Obesity — Phase 2 Trial. NEJM, 2023.
[7]Sanyal AJ et al. Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease. Nature Medicine, 2024.
[8]Sciencedirect. The Power of Three: Retatrutide’s Role in Modern Obesity Therapy. 2024.